Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_3

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642
terminatedphase_3

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187

Clinical Trials (2)

Showing 2 of 2 trials
NCT00447642Phase 3

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Terminated
NCT00447187Phase 3

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2